Home › Ewing Sarcoma › Michigan
Ewing Sarcoma clinical trials in Michigan
8 studies for Ewing Sarcoma are looking for participants at sites in Michigan.
Cities in Michigan
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
- Helen DeVos Children's Hospital, Grand Rapids
RecruitingPhase 1
Ages 1 and older · All sexes · Updated Sep 25, 2026 · NCT07194044Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Corewell Health ( Site 1001), Grand Rapids
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- University of Michigan, Ann Arbor
- START Midwest Michigan, PC, Grand Rapids
RecruitingPhase 1
Ages 12 to 85 · All sexes · Updated Sep 8, 2026 · NCT03715933Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Hospital of Michigan/Wayne State University, Detroit
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Sep 3, 2026 · NCT06541262Lurbinectedin in FET-Fused Tumors
- University of Michigan, Ann Arbor
RecruitingPhase 1/2
Ages 10 and older · All sexes · Updated Sep 2, 2026 · NCT05918640Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- C S Mott Children's Hospital, Ann Arbor
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
- William Beaumont University Hospital, Royal Oak
Recruiting
Ages 13 and older · All sexes · Updated Feb 6, 2026 · NCT06387485Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- Corewell Health, Grand Rapids
RecruitingPhase 1/2
Ages 2 to 30 · All sexes · Updated Feb 3, 2026 · NCT05734066From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.